Comparing a new wet AMD injection to Eylea
Part of Eyes & vision clinical trials.
This study tests a new injection called RBS-001 compared to the standard treatment Eylea for wet age-related macular degeneration (AMD). The goal is to see if the new drug is as safe and effective at improving vision by reducing fluid and blood vessel growth in the eye.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 50 years or older
- You must have active wet AMD in one eye, with fluid buildup and abnormal blood vessels
- Your vision in the study eye should be between 20/200 and 20/40 (approximately 34 to 73 letters on an eye chart)
- You cannot have had prior anti-VEGF treatment for wet AMD in the study eye
- You must not have other serious eye diseases (like diabetic retinopathy or glaucoma) in the study eye
- You must be willing to have regular eye exams and injections for up to 2 years
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a one-time gene therapy injection (4D-150) for wet AMD. It might help reduce the need for frequent anti-VEGF eye injections by targeting the underlying cause of new blood vessel growth.
This trial tests a new investigational injection, QL1207H, against an already approved drug (aflibercept) for people with wet age-related macular degeneration, a condition that causes rapid central vision loss. The goal is to see if the new injection works as well or better at stopping further vision loss and possibly improving sight.
This trial tests an investigational drug called EYE103 injected into the eye to treat two conditions: wet age-related macular degeneration (AMD) or macular edema following a branch retinal vein occlusion (BRVO). It looks at how safe and effective the drug is for people who have not had treatment before or have not responded well to previous treatments.
This study tests whether a new eye injection called ABP 938 works as well as or better than the current standard treatment (Eylea) for wet age-related macular degeneration—a condition that causes vision loss in the center of your sight. You would receive injections into your eye every month for a year.
This trial tests a new injection medicine (AIV007) placed around the eye to treat wet age-related macular degeneration (a condition that damages central vision). You may qualify if you've been treated for this condition before and responded well to previous eye injections.
This Phase 1 trial tests whether BBC1501, an injection given into the eye, is safe for people with wet age-related macular degeneration (nAMD). It mainly looks at side effects and whether the study injections can be given safely in patients who still have active disease despite prior anti-VEGF treatments.
Hear when a new Neovascular Age-Related Macular Degeneration (nAMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.